Gentile, Marino
 Distribuzione geografica
Continente #
NA - Nord America 588
EU - Europa 453
AS - Asia 240
SA - Sud America 50
AF - Africa 5
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 1.342
Nazione #
US - Stati Uniti d'America 582
SE - Svezia 167
SG - Singapore 99
IT - Italia 79
FR - Francia 53
BR - Brasile 46
CN - Cina 44
DE - Germania 44
IN - India 43
IE - Irlanda 41
ID - Indonesia 23
GB - Regno Unito 16
RU - Federazione Russa 9
FI - Finlandia 8
KR - Corea 7
AT - Austria 6
HK - Hong Kong 6
CA - Canada 5
PL - Polonia 5
AU - Australia 4
LT - Lituania 4
TR - Turchia 4
UA - Ucraina 4
AR - Argentina 3
BE - Belgio 3
CZ - Repubblica Ceca 3
GR - Grecia 3
IQ - Iraq 3
MA - Marocco 3
UZ - Uzbekistan 3
CH - Svizzera 2
KZ - Kazakistan 2
LV - Lettonia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BG - Bulgaria 1
EG - Egitto 1
EU - Europa 1
IR - Iran 1
LK - Sri Lanka 1
MX - Messico 1
NL - Olanda 1
PE - Perù 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
VN - Vietnam 1
ZA - Sudafrica 1
Totale 1.342
Città #
Chandler 183
Singapore 77
New York 41
Ashburn 38
Dublin 33
Hyderabad 29
Jakarta 23
Princeton 21
Milan 18
San Mateo 16
Wilmington 15
Frankfurt am Main 13
Marseille 13
Düsseldorf 12
Florence 12
Los Angeles 11
Dearborn 9
Lauterbourg 9
Pune 9
Helsinki 8
Boston 7
Hefei 7
Norwalk 7
Seoul 7
Trieste 7
Garden City 6
Houston 6
London 6
Moscow 6
Beijing 5
Columbus 5
Fairfield 5
Redwood City 5
Benalla 4
Bologna 4
Cattolica 4
Hong Kong 4
Nuremberg 4
Redmond 4
Seattle 4
Vicopisano 4
Washington 4
Bremen 3
Brussels 3
Chicago 3
Falls Church 3
Fremont 3
Genoa 3
Izmir 3
Jacksonville 3
Portsmouth 3
São Paulo 3
Tashkent 3
The Dalles 3
Toronto 3
Wroclaw 3
Andover 2
Bari 2
Brno 2
Central 2
Chengdu 2
Colombo 2
Fortaleza 2
Montes Claros 2
Natal 2
Oshkosh 2
Passo Fundo 2
Ribeirão Preto 2
Riga 2
Rio de Janeiro 2
Rome 2
San Francisco 2
Stockholm 2
Turin 2
Venice 2
Verona 2
'Asir Region 1
Alegrete 1
Almaty 1
Almirante Brown 1
Ann Arbor 1
Arapiraca 1
Araras 1
Asti 1
Athens 1
Atlanta 1
Augusta 1
Baghdad 1
Belo Horizonte 1
Berlin 1
Bern 1
Boa Vista 1
Boardman 1
Botzingen 1
Brasília 1
Brdo 1
Brooklyn 1
Buenos Aires 1
Cabo Frio 1
Cairo 1
Totale 811
Nome #
Adult phenotype in Koolen-de Vries/KANSL1 haploinsufficiency syndrome 106
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study 78
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 76
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 74
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 71
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 71
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 62
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 60
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 59
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 59
Clinical Features of Patients with Cervical Artery Dissection and Fibromuscular Dysplasia 59
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 58
CD49d promotes disease progression in chronic lymphocytic leukemia: New insights from CD49d bimodal expression 57
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 56
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. 55
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 55
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 50
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 48
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 47
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 45
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 43
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 41
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 38
Totale 1.368
Categoria #
all - tutte 8.770
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.770


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 0 0 0 0 0 0 0 0 0 0 4 0
2020/202128 0 0 0 6 0 0 9 0 1 9 1 2
2021/2022233 5 0 49 32 27 5 2 26 7 7 48 25
2022/2023422 58 67 30 64 18 66 15 25 55 3 12 9
2023/2024243 9 59 11 12 15 59 14 12 1 8 14 29
2024/2025409 9 13 31 19 43 20 19 15 57 96 87 0
Totale 1.368